1. Twice-weekly dapsone for primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infection: efficacy, safety and pharmacokinetic data 
M. Cruciani, E. Bertazzoni Minelli, M. Mirandola, R. Luzzati, M. Merighi, L. Lazzarini, G. Gatti, S. Vento, R. Mazzi, M. Malena, A. Benini, A. Cazzadori, G. Piemonte, D. Bassetti, E. Concia 
Clinical Microbiology and Infection 
Volume 2, Issue 1, Pages (August 1996)
DOI: /j tb00197.x
Copyright © 1996 European Society of Clinical Infectious Diseases Terms and Conditions

2. Figure 1
Plasma concentration-time profiles at steady state following the administration of dapsone (100 mg) to three male patients.
Clinical Microbiology and Infection 1996 2, 30-35DOI: ( /j tb00197.x)
Copyright © 1996 European Society of Clinical Infectious Diseases Terms and Conditions

3. Figure 2
Dapsone steady-state concentrations in serum in 42 HIV-infected patients after oral administration (100 mg twice weekly). Δ=mean values; •= female; ∘=male.
Clinical Microbiology and Infection 1996 2, 30-35DOI: ( /j tb00197.x)
Copyright © 1996 European Society of Clinical Infectious Diseases Terms and Conditions